This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability and bioavailability (exploring absorption of drug in body) of NN9925 in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
70
Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
Novo Nordisk Investigational Site
Nottingham, United Kingdom
Number and severity of adverse events (AEs) recorded
Time frame: from dosing to Day 22
The uptake in blood of oral NN9925
Time frame: from 0 to 504 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
Subjects will be randomised to receive a single dose of placebo